![USFDA](https://pharma.industry-report.net/wp-content/uploads/2020/01/USFDA-1.jpg)
Novadoz Pharmaceuticals, the US based sales & marketing affiliate for MSN Labs has received USFDA approval for their generic version of febuxostat 40mg and 80mg tablets.
Febuxostat is a xanthine oxidase inhibitor is indicated for the chronic management of hyperuricemia (elevated levels of uric acid) in adult patients with gout who have a poor response to a maximally titrated dose of Allopurinol.
According to market estimates, the sales figure for a period of 12 months is around US$ 430 million.
Company Profile : MSN Laboratories Ltd
Leave a Reply